Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2910G)

• Drug Name: Anti-VEGFR2 CD8 cell therapy Drug Info
• Synonyms: Anti-VEGFR2 CD8 cell therapy (cancer)

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM2910G

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD8 (CD8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoropeptide vaccine	DMCEUOH	Influenza virus infection	1E30-1E32	Phase 2	[3]
LIPO-4	DMJRALD	Human immunodeficiency virus infection	1C62	Phase 1	[4]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[5]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[6]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[7]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[8]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[9]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[10]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[11]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[12]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[13]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD8 (CD8)	TTMHA6L	CD8A_HUMAN; CD8B_HUMAN	Modulator	[2] , [1]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Modulator	[2] , [1]

References

• [1] ClinicalTrials.gov (NCT01218867) CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer. U.S. National Institutes of Health.
• [2] Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
• [3] A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
• [4] Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
• [5] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [6] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [9] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [10] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [11] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [12] Clinical pipeline report, company report or official report of Exelixis (2011).
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [14] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.